• In recent weeks, Hims & Hers Health launched its Labs AI agent to help users interpret biomarker lab results, expanded access to branded GLP-1 weight-loss drugs through partnerships with Novo Nordisk and Eli Lilly, and confirmed upcoming board changes that will reduce its board size to nine directors while retaining its Global Chief Medical Officer.
• Together, these moves highlight how Hims & Hers is leaning on AI-enabled care and branded obesity treatments to deepen patient engagement and reshape its long-term business mix.
• We’ll now examine how the rollout of Labs AI and branded GLP-1 partnerships may influence Hims & Hers Health’s investment narrative.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Hims & Hers Health Investment Narrative Recap

To be comfortable owning Hims & Hers, you need to believe its telehealth model can keep attracting and retaining subscribers as it leans into AI-enabled care and branded GLP-1 weight loss drugs. In the near term, the key catalyst is how quickly branded GLP-1 memberships scale, while the biggest risk is regulatory and legal pressure around obesity treatments and compounding. The latest Labs AI launch and board changes do not materially alter that risk balance right now.

Among the recent announcements, the expanded access to branded GLP-1 drugs through Novo Nordisk and Eli Lilly stands out as most relevant. It reinforces the current weight loss catalyst by giving eligible patients a clearer path to FDA approved options at a time when compounded GLP-1s face scrutiny. At the same time, it implicitly ties more of Hims & Hers’ growth story to categories where regulation, pricing, and competition are already under close watch.

Yet behind the excitement around new GLP 1 offerings, investors should also be aware of growing legal and regulatory scrutiny around...

Hims & Hers Health's narrative projects $3.6 billion revenue and $248.5 million earnings by 2029.

Uncover how Hims & Hers Health's forecasts yield a $24.31 fair value, a 14% downside to its current price.

Exploring Other Perspectives

Some of the lowest priced analysts took a much tougher stance, assuming revenue of about US$3.1 billion and earnings near US$269 million by 2028, and arguing that heavier regulation and thinner margins from GLP 1 and other core categories could justify a far lower share price than today, so it is worth comparing their assumptions with the latest AI and obesity drug news before you decide which narrative you find more convincing.

Explore 46 other fair value estimates on Hims & Hers Health - why the stock might be worth over 6x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.